Top

Pituitary

Published in:

01-04-2015

Surgical management of Cushing’s disease

Authors: Robert F. Dallapiazza, Edward H. Oldfield, John A. Jane Jr.

Published in: Pituitary | Issue 2/2015

Abstract

Background

Transsphenoidal selective adenomectomy is the first-line treatment for Cushing’s disease. At experienced centers, early remission rates after transsphenoidal surgery range from 65 to 98 %, however disease relapse frequently occurs with rates ranging from 2 to 35 % at long-term follow up.

Methods

This article discusses recently reported studies on the surgical outcomes from transsphenoidal surgery for Cushing's disease.

Conclusions

One of the keys to a successful long-term surgical outcome is meticulous dissection using the adenoma’s pseudocapsule as a surgical plane for complete resection. MRI-negative and invasive ACTH-secreting adenomas pose particular challenges for pituitary surgeons.

Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632–642CrossRefPubMed

Dekkers OM, Biermasz NR, Pereira AM et al (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(3):976–981CrossRefPubMed

Swearingen B, Biller BM, Barker FG II et al (1999) Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130(10):821–824CrossRefPubMed

Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967–973CrossRefPubMed

Ciric I, Zhao JC, Du H et al (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70(1):70–80 (discussion 80–71)CrossRefPubMedCentralPubMed

Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348–6357CrossRefPubMed

Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Muller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18CrossRefPubMed

Jagannathan J, Smith R, DeVroom HL et al (2009) Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 111(3):531–539CrossRefPubMedCentralPubMed

Pouratian N, Prevedello DM, Jagannathan J, Lopes MB, Vance ML, Laws ER Jr (2007) Outcomes and management of patients with Cushing’s disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab 92(9):3383–3388CrossRefPubMed

10.

Prevedello DM, Pouratian N, Sherman J et al (2008) Management of Cushing’s disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 109(4):751–759CrossRefPubMed

11.

Dickerman RD, Oldfield EH (2002) Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97(6):1343–1349CrossRefPubMed

12.

Bertagna X, Guignat L (2013) Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98(4):1307–1318CrossRefPubMed

13.

Friedman RB, Oldfield EH, Nieman LK et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527CrossRefPubMed

14.

McLaughlin N, Kassam AB, Prevedello DM, Kelly DF (2011) Management of Cushing’s disease after failed surgery—a review. Can J Neurol Sci 38(1):12–21CrossRefPubMed

15.

Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH (1994) Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80(1):37–45CrossRefPubMed

16.

Valderrabano P, Aller J, Garcia-Valdecasas L et al (2014) Results of repeated transsphenoidal surgery in Cushing’s disease. Long-term follow-up. Endocrinol Nutr 61(4):176–183CrossRefPubMed

17.

Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing’s disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61 (discussion 61–52)CrossRefPubMed

18.

Patil CG, Prevedello DM, Lad SP et al (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358–362CrossRefPubMed

19.

Alahmadi H, Cusimano MD, Woo K et al (2013) Impact of technique on cushing disease outcome using strict remission criteria. Can J Neurol Sci 40(3):334–341CrossRefPubMed

20.

Alexandraki KI, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 68(4):639–648CrossRef

21.

Aranda G, Ensenat J, Mora M et al (2015) Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up. Pituitary 18(1):142–149CrossRefPubMed

22.

Berker M, Isikay I, Berker D, Bayraktar M, Gurlek A (2013) Early promising results for the endoscopic surgical treatment of Cushing’s disease. Neurosurg Rev (Epub ahead of print; PMID: 24233258)

23.

Costenaro F, Rodrigues TC, Rollin GA, Ferreira NP, Czepielewski MA (2014) Evaluation of Cushing’s disease remission after transsphenoidal surgery based on early serum cortisol dynamics. Clin Endocrinol 80(3):411–418CrossRef

24.

Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M, Stalla GK (2013) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol 170(2):283–292CrossRefPubMed

25.

Hameed N, Yedinak CG, Brzana J et al (2013) Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16(4):452–458CrossRefPubMed

26.

Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab 98(3):1022–1030CrossRefPubMedCentralPubMed

27.

Starke RM, Reames DL, Chen CJ, Laws ER, Jane JA Jr (2013) Endoscopic transsphenoidal surgery for cushing disease: techniques, outcomes, and predictors of remission. Neurosurgery 72(2):240–247 (discussion 247)CrossRefPubMed

28.

Wagenmakers MA, Boogaarts HD, Roerink SH et al (2013) Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing’s disease, even in case of macroadenomas or invasive adenomas. Eur J Endocrinol 169(3):329–337CrossRefPubMed

29.

Lonser RR, Wind JJ, Nieman LK, Weil RJ, DeVroom HL, Oldfield EH (2013) Outcome of surgical treatment of 200 children with Cushing’s disease. J Clin Endocrinol Metabol 98(3):892–901CrossRef

30.

Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK (2011) The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J Clin Endocrinol Metab 96(7):2057–2064CrossRefPubMedCentralPubMed

31.

Nakane T, Kuwayama A, Watanabe M et al (1987) Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 21(2):218–222CrossRefPubMed

32.

Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB Jr, Loriaux DL (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527CrossRefPubMed

33.

Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER Jr (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63(2):266–270 (discussion 270–271)CrossRefPubMed

34.

Kawamata T, Kubo O, Hori T (2005) Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly. Neurosurg Rev 28(3):201–208CrossRefPubMed

35.

Oldfield EH (2011) Surgical management of Cushing’s disease: a personal perspective. Clin Neurosurg 58:13–26CrossRefPubMed

36.

Oldfield EH, Vortmeyer AO (2006) Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg 104(1):7–19CrossRefPubMed

37.

Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116(4):721–727CrossRefPubMed

38.

Kasaliwal R, Sankhe SS, Lila AR et al (2013) Volume interpolated 3D-spoiled gradient echo sequence is better than dynamic contrast spin echo sequence for MRI detection of corticotropin secreting pituitary microadenomas. Clin Endocrinol 78(6):825–830CrossRef

39.

Patronas N, Bulakbasi N, Stratakis CA et al (2003) Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 88(4):1565–1569CrossRefPubMed

40.

Yamada S, Fukuhara N, Nishioka H et al (2012) Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg 77(3–4):525–532CrossRefPubMed

41.

Batista D, Courkoutsakis NA, Oldfield EH et al (2005) Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease. J Clin Endocrinol Metab 90(9):5134–5140CrossRefPubMed

42.

Oldfield EH, Doppman JL, Nieman LK et al (1991) Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 325(13):897–905CrossRefPubMed

43.

Wind JJ, Lonser RR, Nieman LK, DeVroom HL, Chang R, Oldfield EH (2013) The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing’s disease. J Clin Endocrinol Metab 98(6):2285–2293CrossRefPubMedCentralPubMed

44.

Oldfield EH, Vance ML (2013) A cryptic cause of Cushing’s disease. J Clin Endocrinol Metab 98(12):4593–4594CrossRefPubMed

45.

Pluta RM, Nieman L, Doppman JL et al (1999) Extrapituitary parasellar microadenoma in Cushing’s disease. J Clin Endocrinol Metab 84(8):2912–2923PubMed

46.

Weil RJ, Vortmeyer AO, Nieman LK, Devroom HL, Wanebo J, Oldfield EH (2006) Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing’s disease. J Clin Endocrinol Metab 91(7):2656–2664CrossRefPubMed

47.

Oldfield EH (2014) Editorial: Management of invasion by pituitary adenomas. J Neurosurg 121(3):501–503CrossRefPubMed

48.

Kakade HR, Kasaliwal R, Khadilkar KS et al (2014) Clinical, biochemical and imaging characteristics of Cushing’s macroadenomas and their long-term treatment outcome. Clin Endocrinol 81(3):336–342CrossRef

49.

Lonser RR, Ksendzovsky A, Wind JJ, Vortmeyer AO, Oldfield EH (2012) Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg 116(2):272–279CrossRefPubMed

Title: Surgical management of Cushing’s disease
Authors: Robert F. Dallapiazza
Edward H. Oldfield
John A. Jane Jr.
Publication date: 01-04-2015
Publisher: Springer US
Published in: Pituitary / Issue 2/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-015-0646-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

A pitfall in diagnosing Cushing’s disease: ectopic ACTH-producing pituitary adenoma in the sphenoid sinus

Update on radiation therapy in patients with Cushing’s disease

Screening for Cushing’s syndrome: Is it worthwhile?

Approach to the postoperative patient with Cushing’s disease

Cushing disease: Where do we stand, where are we heading?

Comorbidities in Cushing’s disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials